Deals

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC
AstraZenecaDizal Pharmaceutical

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA: 688192) announced that it has received a US$600 million upfront payment from AstraZeneca plc (NYSE: AZN), stemming from the global exclusive licensing agreement for…

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Vcare Pharma Partners with CTTQ Subsidiary to Commercialize Eratrectinib – Next‑Generation TRK Inhibitor Approved in China for NTRK Fusion Solid Tumors

Vcare Pharma Partners with CTTQ Subsidiary to Commercialize Eratrectinib – Next‑Generation TRK Inhibitor Approved in China for NTRK Fusion Solid Tumors

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Jiangsu Vcare PharmaTech Secures RMB200 Million in Series C+ Financing
BiotechCRO / CMO / CDMO

Jiangsu Vcare PharmaTech Secures RMB200 Million in Series C+ Financing

GeneQuantum Secures $13 Billion Deals with Biohaven and AimedBio for ADC Development
ADC / XDCAimed Bio

GeneQuantum Secures $13 Billion Deals with Biohaven and AimedBio for ADC Development

Sinopharm Partners with Biogen for Comprehensive Service Agreement
BiogenHKG: 1099

Sinopharm Partners with Biogen for Comprehensive Service Agreement

Mirxes Holding Files for Hong Kong IPO with Focus on miRNA Test Kits
IPOMirxes

Mirxes Holding Files for Hong Kong IPO with Focus on miRNA Test Kits

Show More